This company listing is no longer active
IMMNOV BTA Stock Overview
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Immunovia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr4.08 |
| 52 Week High | kr6.80 |
| 52 Week Low | kr3.90 |
| Beta | 1.37 |
| 1 Month Change | -40.00% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -40.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMMNOV BTA | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -0.2% | 2.7% | 1.1% |
| 1Y | n/a | -6.9% | 10.2% |
Return vs Industry: Insufficient data to determine how IMMNOV BTA performed against the Swedish Medical Equipment industry.
Return vs Market: Insufficient data to determine how IMMNOV BTA performed against the Swedish Market.
Price Volatility
| IMMNOV BTA volatility | |
|---|---|
| IMMNOV BTA Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.3% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: IMMNOV BTA's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine IMMNOV BTA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 64 | Jeff Borcherding | www.immunovia.com |
Immunovia AB (publ), a diagnostic company, develops and commercializes blood-based diagnostics for cancer in Sweden and internationally. It offers IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. The company was incorporated in 2007 and is headquartered in Lund, Sweden.
Immunovia AB (publ) Fundamentals Summary
| IMMNOV BTA fundamental statistics | |
|---|---|
| Market cap | kr193.60m |
| Earnings (TTM) | -kr168.09m |
| Revenue (TTM) | kr1.15m |
169.1x
P/S Ratio-1.2x
P/E RatioIs IMMNOV BTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMNOV BTA income statement (TTM) | |
|---|---|
| Revenue | kr1.15m |
| Cost of Revenue | kr4.21m |
| Gross Profit | -kr3.07m |
| Other Expenses | kr165.03m |
| Earnings | -kr168.09m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
May 23, 2023
| Earnings per share (EPS) | -3.71 |
| Gross Margin | -267.77% |
| Net Profit Margin | -14,680.52% |
| Debt/Equity Ratio | 0% |
How did IMMNOV BTA perform over the long term?
See historical performance and comparison